Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms

Jin Wook Kim, Mi-Mi Oh, Jeong Kyun Yeo, Jae Hyun Bae, Kwan Joong Joo, Jong Bo Choi, Hong Seok Park, Hyung Jee Kim, Du Geon Moon, Jeong Gu Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: The aim of this study was to compare the efficacy of low (0.2 mg) and intermediate (0.4 mg) dose tamsulosin in treating lower urinary tract symptoms (LUTS). Methods: Patients were treated with low-dose tamsulosin for an initial run-in period of 12 weeks, then divided into two groups based on their clinical improvement. Patients were measured for objective parameters of peak flow rate and postvoid residual urine volume, as well as subjective symptom scores and perceived patient benefit of treatment. The items were then integrated as the LUTS Outcome Score to determine dose increase or maintenance. Overall outcome was determined at 36 weeks. Results: One hundred and seventy-four patients were enrolled and started on 0.2 mg tamsulosin treatment. One hundred and fifty-five patients completed the 36-week study. Sixty patients required dose increase to 0.4 mg at the 12th week. Baseline characteristics showed that a patient who would benefit from 0.4 mg dosage had higher age, daytime frequency, and lower peak urine flow rate. Patients receiving both 0.2 and 0.04 mg both showed improved clinical outcome measures. Higher improvement was found in voiding component symptom scores and urine flow rate improvement in patients receiving an increased dose. Conclusion: Both low- and intermediate-dose tamsulosin are effective treatment regimens. Increasing from low to intermediate dose should follow assessment of both objective and subjective improvements.

Original languageEnglish
Pages (from-to)96-102
Number of pages7
JournalLUTS: Lower Urinary Tract Symptoms
Volume4
Issue number2
DOIs
Publication statusPublished - 2012 May 1

Fingerprint

tamsulosin
Lower Urinary Tract Symptoms
Therapeutics
Urine
Residual Volume

Keywords

  • Adrenergic alpha-antagonist
  • Benign prostatic hyperplasia
  • Drug therapy
  • Tamsulosin

ASJC Scopus subject areas

  • Neurology
  • Urology

Cite this

Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms. / Kim, Jin Wook; Oh, Mi-Mi; Yeo, Jeong Kyun; Bae, Jae Hyun; Joo, Kwan Joong; Choi, Jong Bo; Park, Hong Seok; Kim, Hyung Jee; Moon, Du Geon; Lee, Jeong Gu.

In: LUTS: Lower Urinary Tract Symptoms, Vol. 4, No. 2, 01.05.2012, p. 96-102.

Research output: Contribution to journalArticle

@article{59248073d9784c21a8468227ef58d3e0,
title = "Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms",
abstract = "Objectives: The aim of this study was to compare the efficacy of low (0.2 mg) and intermediate (0.4 mg) dose tamsulosin in treating lower urinary tract symptoms (LUTS). Methods: Patients were treated with low-dose tamsulosin for an initial run-in period of 12 weeks, then divided into two groups based on their clinical improvement. Patients were measured for objective parameters of peak flow rate and postvoid residual urine volume, as well as subjective symptom scores and perceived patient benefit of treatment. The items were then integrated as the LUTS Outcome Score to determine dose increase or maintenance. Overall outcome was determined at 36 weeks. Results: One hundred and seventy-four patients were enrolled and started on 0.2 mg tamsulosin treatment. One hundred and fifty-five patients completed the 36-week study. Sixty patients required dose increase to 0.4 mg at the 12th week. Baseline characteristics showed that a patient who would benefit from 0.4 mg dosage had higher age, daytime frequency, and lower peak urine flow rate. Patients receiving both 0.2 and 0.04 mg both showed improved clinical outcome measures. Higher improvement was found in voiding component symptom scores and urine flow rate improvement in patients receiving an increased dose. Conclusion: Both low- and intermediate-dose tamsulosin are effective treatment regimens. Increasing from low to intermediate dose should follow assessment of both objective and subjective improvements.",
keywords = "Adrenergic alpha-antagonist, Benign prostatic hyperplasia, Drug therapy, Tamsulosin",
author = "Kim, {Jin Wook} and Mi-Mi Oh and Yeo, {Jeong Kyun} and Bae, {Jae Hyun} and Joo, {Kwan Joong} and Choi, {Jong Bo} and Park, {Hong Seok} and Kim, {Hyung Jee} and Moon, {Du Geon} and Lee, {Jeong Gu}",
year = "2012",
month = "5",
day = "1",
doi = "10.1111/j.1757-5672.2012.00141.x",
language = "English",
volume = "4",
pages = "96--102",
journal = "LUTS: Lower Urinary Tract Symptoms",
issn = "1757-5664",
publisher = "Wiley Blackwell",
number = "2",

}

TY - JOUR

T1 - Efficacy of Dose Escalation of Tamsulosin for the Treatment of Lower Urinary Tract Symptoms

AU - Kim, Jin Wook

AU - Oh, Mi-Mi

AU - Yeo, Jeong Kyun

AU - Bae, Jae Hyun

AU - Joo, Kwan Joong

AU - Choi, Jong Bo

AU - Park, Hong Seok

AU - Kim, Hyung Jee

AU - Moon, Du Geon

AU - Lee, Jeong Gu

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Objectives: The aim of this study was to compare the efficacy of low (0.2 mg) and intermediate (0.4 mg) dose tamsulosin in treating lower urinary tract symptoms (LUTS). Methods: Patients were treated with low-dose tamsulosin for an initial run-in period of 12 weeks, then divided into two groups based on their clinical improvement. Patients were measured for objective parameters of peak flow rate and postvoid residual urine volume, as well as subjective symptom scores and perceived patient benefit of treatment. The items were then integrated as the LUTS Outcome Score to determine dose increase or maintenance. Overall outcome was determined at 36 weeks. Results: One hundred and seventy-four patients were enrolled and started on 0.2 mg tamsulosin treatment. One hundred and fifty-five patients completed the 36-week study. Sixty patients required dose increase to 0.4 mg at the 12th week. Baseline characteristics showed that a patient who would benefit from 0.4 mg dosage had higher age, daytime frequency, and lower peak urine flow rate. Patients receiving both 0.2 and 0.04 mg both showed improved clinical outcome measures. Higher improvement was found in voiding component symptom scores and urine flow rate improvement in patients receiving an increased dose. Conclusion: Both low- and intermediate-dose tamsulosin are effective treatment regimens. Increasing from low to intermediate dose should follow assessment of both objective and subjective improvements.

AB - Objectives: The aim of this study was to compare the efficacy of low (0.2 mg) and intermediate (0.4 mg) dose tamsulosin in treating lower urinary tract symptoms (LUTS). Methods: Patients were treated with low-dose tamsulosin for an initial run-in period of 12 weeks, then divided into two groups based on their clinical improvement. Patients were measured for objective parameters of peak flow rate and postvoid residual urine volume, as well as subjective symptom scores and perceived patient benefit of treatment. The items were then integrated as the LUTS Outcome Score to determine dose increase or maintenance. Overall outcome was determined at 36 weeks. Results: One hundred and seventy-four patients were enrolled and started on 0.2 mg tamsulosin treatment. One hundred and fifty-five patients completed the 36-week study. Sixty patients required dose increase to 0.4 mg at the 12th week. Baseline characteristics showed that a patient who would benefit from 0.4 mg dosage had higher age, daytime frequency, and lower peak urine flow rate. Patients receiving both 0.2 and 0.04 mg both showed improved clinical outcome measures. Higher improvement was found in voiding component symptom scores and urine flow rate improvement in patients receiving an increased dose. Conclusion: Both low- and intermediate-dose tamsulosin are effective treatment regimens. Increasing from low to intermediate dose should follow assessment of both objective and subjective improvements.

KW - Adrenergic alpha-antagonist

KW - Benign prostatic hyperplasia

KW - Drug therapy

KW - Tamsulosin

UR - http://www.scopus.com/inward/record.url?scp=84859977739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859977739&partnerID=8YFLogxK

U2 - 10.1111/j.1757-5672.2012.00141.x

DO - 10.1111/j.1757-5672.2012.00141.x

M3 - Article

VL - 4

SP - 96

EP - 102

JO - LUTS: Lower Urinary Tract Symptoms

JF - LUTS: Lower Urinary Tract Symptoms

SN - 1757-5664

IS - 2

ER -